By Fineline Cube Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that Australia’s Therapeutic Goods Administration (TGA) has granted approval to initiate a Phase I clinical study evaluating HLX3902, a trispecific T-cell engager targeting STEAP1, CD3, and CD28, in patients with metastatic castration-resistant prostate cancer (mCRPC) and other advanced solid tumors.
Regulatory & Development Milestone
| Item | Detail |
|---|---|
| Regulatory Agency | Therapeutic Goods Administration (TGA), Australia |
| Trial Phase | Phase I (first-in-human) |
| Primary Indication | Metastatic castration-resistant prostate cancer (mCRPC) |
| Additional Indications | Other advanced solid tumors |
| Molecule Type | Trispecific T-cell engager |
| Targets | STEAP1 (tumor antigen), CD3 (T-cell activation), CD28 (T-cell co-stimulation) |
| Development Status | Independently developed by Henlius Biotech |
Novel Mechanism of Action
- Triple-Targeting Design: HLX3902 simultaneously engages STEAP1-expressing tumor cells, CD3 on T-cells (primary activation signal), and CD28 on T-cells (co-stimulatory signal)
- Enhanced T-Cell Activation: By optimizing both the first signal (CD3) and second signal (CD28), HLX3902 achieves superior T-cell activation compared to conventional bispecific engagers
- Comprehensive Immune Response: Promotes enhanced T-cell proliferation, survival, and cytotoxic activity against tumor targets
- Target Rationale: STEAP1 is highly expressed in prostate cancer and various solid tumors, providing tumor-selective targeting while sparing healthy tissues
- Preclinical Validation: Demonstrated favorable anti-tumor efficacy and safety profiles in preclinical models, supporting clinical translation
Strategic Implications & Market Opportunity
- Technology Leadership: HLX3902 represents one of the industry’s first trispecific T-cell engagers to enter clinical development, showcasing Henlius’ advanced immunotherapy platform capabilities
- Prostate Cancer Focus: mCRPC remains a high-unmet-need indication with limited effective therapies after androgen receptor pathway inhibition failure
- Global Development Strategy: Australian regulatory approval enables international clinical trial execution, facilitating potential global registration pathways and partnership opportunities
- Platform Expansion Potential: Success of HLX3902 would validate Henlius’ trispecific engager platform, enabling rapid development of additional candidates targeting different tumor antigens
- Competitive Differentiation: The dual co-stimulation approach (CD3 + CD28) addresses limitations of current T-cell engagers that rely solely on CD3 activation, potentially improving efficacy while maintaining manageable safety profiles
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial initiation, regulatory approvals, and development expectations for HLX3902. Actual results may differ due to risks including trial outcomes, safety findings, and competitive dynamics.-Fineline Info & Tech